Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
Pablo Rodríguez de Vera-GómezMariola Méndez MurosAlberto Torres CuadroFrancisco Javier Toyos Sáenz de MieraRocío López RuizRaquel Guerrero VázquezJuan Jesús García GonzálezAntonio Manuel Garrido HermosillaTomás Martín HernándezPublished in: Journal of neurology (2023)
We report one of the largest cohorts of GD-ALZ and GO-ALZ cases. The diagnosis of these entities should be taken into account in patients treated with Alemtuzumab, given the risk of developing severe clinical forms. In moderate-severe forms of GO-ALZ, drugs with anti-IL-6 activity are a safe and effective option.